All In Biotech

Drug Trial Radar · NCT02761057

Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed

A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)

Last checked: Nov 19, 2026Latest source record: Jan 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 152 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

152

Actual

Start

Jul 25, 2016

Primary completion

Oct 19, 2023

Study completion Oct 19, 2023

Sponsor

Sponsor type
NIH
Collaborators
Canadian Cancer Trials Group
First posted
May 4, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial studies how well cabozantinib s-malate, crizotinib, savolitinib, or sunitinib malate work in treating patients with kidney cancer that has spread from where it started to nearby tissue or lymph nodes or to other places in the body. Cabozantinib s-malate, crizotinib, savolitinib, and sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether giving cabozantinib s-malate, crizotinib, or savolitinib will work better in treating patients with kidney cancer compared to sunitinib malate.

Conditions

  • Locally Advanced Papillary Renal Cell Carcinoma
  • Metastatic Papillary Renal Cell Carcinoma
  • Stage III Renal Cell Cancer AJCC v7
  • Stage IV Renal Cell Cancer AJCC v7
  • Type 1 Papillary Renal Cell Carcinoma
  • Type 2 Papillary Renal Cell Carcinoma
  • Unresectable Renal Cell Carcinoma

Interventions

  • Biospecimen CollectionProcedure

    Undergo collection of plasma and serum samples

  • Bone ScanProcedure

    Undergo bone scan

  • Cabozantinib S-malateDrug

    Given PO

  • Computed TomographyProcedure

    Undergo CT

  • CrizotinibDrug

    Given PO

  • SavolitinibDrug

    Given PO

  • Sunitinib MalateDrug

    Given PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS)Time frame: From date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause; assessed up to 3 years

Locations

595 sites in 2 countries. Site status is shown where the registry gives one.

  • Anchorage Associates in Radiation Medicine

    Anchorage, Alaska

  • Anchorage Radiation Therapy Center

    Anchorage, Alaska

  • Alaska Breast Care and Surgery LLC

    Anchorage, Alaska

  • Alaska Oncology and Hematology LLC

    Anchorage, Alaska

  • Alaska Women's Cancer Care

    Anchorage, Alaska

  • Anchorage Oncology Centre

    Anchorage, Alaska

  • Katmai Oncology Group

    Anchorage, Alaska

  • Providence Alaska Medical Center

    Anchorage, Alaska

  • Kingman Regional Medical Center

    Kingman, Arizona

  • Mercy Hospital Fort Smith

    Fort Smith, Arkansas

  • John L McClellan Memorial Veterans Hospital

    Little Rock, Arkansas

  • PCR Oncology

    Arroyo Grande, California

  • Sutter Auburn Faith Hospital

    Auburn, California

  • Sutter Cancer Centers Radiation Oncology Services-Auburn

    Auburn, California

  • AIS Cancer Center at San Joaquin Community Hospital

    Bakersfield, California

  • Alta Bates Summit Medical Center-Herrick Campus

    Berkeley, California

  • Providence Saint Joseph Medical Center/Disney Family Cancer Center

    Burbank, California

  • Mills-Peninsula Medical Center

    Burlingame, California

  • Sutter Cancer Centers Radiation Oncology Services-Cameron Park

    Cameron Park, California

  • Eden Hospital Medical Center

    Castro Valley, California

  • Sutter Davis Hospital

    Davis, California

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • Epic Care-Dublin

    Dublin, California

  • Bay Area Breast Surgeons Inc

    Emeryville, California

  • Epic Care Partners in Cancer Care

    Emeryville, California

  • Palo Alto Medical Foundation-Fremont

    Fremont, California

  • Los Angeles General Medical Center

    Los Angeles, California

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California

  • Cedars Sinai Medical Center

    Los Angeles, California

  • Contra Costa Regional Medical Center

    Martinez, California

  • Fremont - Rideout Cancer Center

    Marysville, California

  • Memorial Medical Center

    Modesto, California

  • Palo Alto Medical Foundation-Camino Division

    Mountain View, California

  • Palo Alto Medical Foundation-Gynecologic Oncology

    Mountain View, California

  • USC Norris Oncology/Hematology-Newport Beach

    Newport Beach, California

  • Sutter Cancer Research Consortium

    Novato, California

  • Alta Bates Summit Medical Center - Summit Campus

    Oakland, California

  • Bay Area Tumor Institute

    Oakland, California

  • Palo Alto Medical Foundation Health Care

    Palo Alto, California

  • Keck Medical Center of USC Pasadena

    Pasadena, California

Showing 40 of 595 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.